$599

Abbott and Roche Q1 ’19 Earnings Updates

Abbott and Roche hosted their respective Q1 ’19 earnings calls and provided brief updates to their diabetes businesses. Of note, Abbott disclosed its Libre 2 US filing includes a request for iCGM designation. Below, FENIX provides highlights and insights from the calls.

This content is for Read Less members only.
Register
Already a member? Log in here